Content
All Posts > Content under Pharma/Biotech
Flashback To The 70’s
Article By:
Keith Schneider
Read
Sunday, September 22, 2019 11:15 AM EDT
Global equity markets had a moment of self doubt and most country ETFs backed off after digesting lower rates in the US. The thinking behind the tepid market response had some logic as the Fed stated they were concerned about an economic slowdown.
Week In Review: Investor Group Bids $4.6 Billion To Acquire China Biologic
Article By:
ChinaBio® Today
Read
Saturday, September 21, 2019 4:41 PM EDT
China Biologic Products, a blood products company, received a $4.6 billion takeover offer that is similar to a proposal the company rejected one year ago.
Bull Of The Day: Amgen (AMGN)
Article By:
Zacks Investment Research
Read
Friday, September 20, 2019 9:52 AM EDT
Amgen is so far past that stage that they look attractive on a valuation basis just based on current lines of business. The potential for new best-selling drugs is just gravy for shareholders.
In this article: AMGN
Bull Of The Day - GW Pharmaceuticals
Article By:
Kevin Cook
Read
Thursday, September 19, 2019 10:02 AM EDT
GW Pharma delivered a bigger sales beat for Epidiolex than even the most optimistic analysts were projecting. GWPH crushed the sales number for the treatment of two rare forms of pediatric epilepsy with $68 million vs. consensus of $45M.
In this article: GWPH
Week In Review: Hansoh Signs $1.5 Billion Cross-Border Deal For AI-Drug Discovery With Atomwise
Article By:
ChinaBio® Today
Read
Saturday, September 14, 2019 4:53 PM EDT
China's Hansoh Pharma formed an AI-based small molecule drug discovery collaboration worth up to $1.5 billion with Atomwise of San Francisco.
Japan Drug Firm Bets $3 Billion On Castoffs And Hype
Article By:
Lipper Alpha Insight
Read
Monday, September 9, 2019 9:05 PM EDT
The lucrative deal with Sumitomo is just the treatment Roivant needs to keep its model ticking. But it’s unlikely to fix what ails its Japanese partner.
In this article: DNPUF
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By:
T.J. Hayes
Read
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Portfolio Highlights - September 2019
Article By:
Ingrid Hendershot
Read
Monday, September 9, 2019 2:15 PM EDT
During the past three months, the S&P 500 Index rose 2.1% despite renewed concerns over a trade war and slowing global growth. The following high-quality stocks all generated solid 9% or better gains during the same period.
Week In Review: PAG Pays $540 Million For 58% Stake In Hisun BioRay, A China Biotech
Article By:
ChinaBio® Today
Read
Saturday, September 7, 2019 4:35 PM EDT
PAG, a Hong Kong PE firm, will pay $540 million to acquire a 58% stake in Hisun BioRay, a China biologics company developing autoimmune and oncology drugs.
CGC: Better Safe Than Sorry
Article By:
Christian Stoyanov
Read
Saturday, September 7, 2019 3:52 PM EDT
Recently Canopy Growth Corp. (CGC) has reached its 12 month low, mainly due to excessive cash burns and disappointing results. Even so, I do not find solid underlying company fundamentals for investing in it.
In this article: CGC
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Article By:
Terry Chrisomalis
Read
Thursday, September 5, 2019 8:46 AM EDT
Bellicum is a highly undervalued biotech. Especially, when you consider that it has two types of technology that can be utilized to potentially alter how CAR-T therapies are produced.
In this article: BLCM
The Stock Market Stands On A Precarious Scaffold
Article By:
Michele Schneider
Read
Sunday, September 1, 2019 10:15 AM EDT
In the current market, the price action and negative phases in the indices hang precariously. The bulls, nevertheless, continue to trust the scaffolding of low interest rates, hope for a resolution of tariffs and positive economic statistics.